Table 3.

EGFR and PDGFR inhibitors under investigation for the treatment of malignant glioma

EGFR inhibitorPDGFR inhibitor
Erlotinib (OSI 774, Tarceva; Genentech)Imatinib mesylate (Gleevec, STI1571; Novartis)
Gefitinib (ZD1839, Iressa; AstraZeneca)Sorafenib (Bay 43-9006; ONYX/Bayer)
Cetuximab (C225, Erbitux; Merck)SU011248 (Sutent; Pfizer)
ZD6474 (Zactima) AstraZenecaPazopanib (GW786034; GlaxoSmithKline)
Lapatinib (GW-572016; GlaxoSmithKline)PTK787 (Novartis/Schering)
AEE788 (Novartis)AMG706 (Amgen)
EKB569 (Wyeth Ayerst)